{{Drugbox
| verifiedrevid = 447766566
| IUPAC_name =  
| image =  
| image2 = Motexafin gadolinium 3D sticks.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 156436-89-4
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 158385
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 139341
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05080
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 50161

<!--Chemical data-->
| chemical_formula =  
| C=52 | H=72 | Gd=1 | N=5 | O=14 
| molecular_weight = 1148.403 g/mol
| smiles = [Gd+3].[O-]C(=O)C.[O-]C(=O)C.n1c3\C(=C(/c1cnc5cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc5ncc/4nc(cc2[n-]c(c(c2CC)CC)c3)\C(=C\4C)CCCO)C)CCCO
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C48H66N5O10.2C2H4O2.Gd/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);/q-1;;;+3/p-2/b39-27-,40-28-,41-27-,42-28-,45-31-,46-32-,49-31+,49-43+,50-32+,50-44+;;;
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VAZLWPAHMORDGR-WRIGXHCHSA-L
}}

'''Motexafin gadolinium''' (proposed tradename '''Xcytrin''') is an inhibitor of [[thioredoxin reductase]] and [[ribonucleotide reductase]]. It has been proposed as a possible [[chemotherapy|chemotherapeutic agent]] in the treatment of [[brain metastases]].<ref>{{cite journal |vauthors=Richards G, Mehta M |title=Motexafin gadolinium in the treatment of brain metastases |journal=Expert opinion on pharmacotherapy |volume=8 |issue=3 |pages=351â€“9 |year=2007 |pmid=17266469 |doi=10.1517/14656566.8.3.351}}</ref>

==History==
On May 9, 2006, a New Drug Application was submitted to the [[United States]] [[Food and Drug Administration]] (FDA) by Pharmacyclics, Inc.<ref>[http://www.drugs.com/nda/xcytrin_060509.html   Pharmacyclics, Inc. press release - Pharmacyclics to Submit New Drug Application for Xcytrin for Treatment of Lung Cancer Patients With Brain Metastases]</ref>

On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.<ref>[http://www.drugs.com/nda/xcytrin_071226.html   Pharmacyclics, Inc. press release - Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases]</ref>

==References==
<references/>

[[Category:Gadolinium compounds]]


{{biochemistry-stub}}